Cannabinoid Receptor Antagonist

Cannabinoid Receptor Antagonists (39):

Cat. No.	Product Name	Effect	Purity

HY-15443

AM251	Antagonist	98.04%
AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC₅₀ of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC₅₀ of 39 nM.

HY-14137

Rimonabant Hydrochloride	Antagonist	99.95%
Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an K_i of 1.8 nM. Rimonabant Hydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-18697

JD-5037	Antagonist	98.05%
JD-5037 is a potent CB₁R antagonist with an IC₅₀ of 1.5 nM.

HY-13439

SR144528	Antagonist	99.86%
SR144528 is a potent and selective CB2 receptor antagonist with a K_i of 0.6 nM.

HY-112340

TM38837	Antagonist	99.00%
TM38837 is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. TM38837 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects. TM38837 reduces propensity for psychiatric side effects.

HY-14791A

(±)-Ibipinabant	Antagonist	99.90%
(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC₅₀ of 22 nM.

HY-13505

AM281	Antagonist	≥99.0%
AM281 is a selective CB1 receptor antagonist with an IC₅₀ of 9.91 nM. AM281 inhibits CB2 receptor with an IC₅₀ of 13000 nM.

HY-120423

AM-6538	Antagonist	99.73%
AM6538 is a long-acting, high affinity and pseudo-irreversible cannabinoid (CB) antagonist. AM6538 is a structural analog of rimonabant. AM6538 can be effectively used to evaluate the apparent efficacy of cannabinoid full and partial agonists. AM6538 may be useful in future studies that require temporary reductions in cannabinoid receptor availability.

HY-10871

Otenabant	Antagonist	99.33%
Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-116649

CB1 antagonist 2	Antagonist	99.88%
CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1, compound 3, inhibits CB1 in vivo with an IC₅₀ of 25.5 nM.

HY-10013A

Taranabant racemate	Antagonist	99.58%
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the Cannabinoid-1 (CB1) receptor extracted from patent WO 2004048317 A1.

HY-N6932

Voacamine	Antagonist	98.16%
Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity. Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells.

HY-12790

CB1-IN-1	Antagonist	99.31%
CB1-IN-1 (BPRCB1184) is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.

HY-117139

NESS 0327	Antagonist	≥98.0%
NESS 0327 is a cannabinoid antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor.

HY-14136

Rimonabant	Antagonist
Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a K_i of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-10871A

Otenabant Hydrochloride	Antagonist
Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-141411A

Zevaquenabant	Antagonist
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).

HY-110179

PSNCBAM-1	Antagonist
PSNCBAM-1 is a selective CB1 receptor allosteric antagonist with an EC₅₀ of 0.1 μM. PSNCBAM-1 can be used in the researches of obesity.

HY-121616

(R)-SLV 319	Antagonist
(R)-SLV 319 is a potent and selective cannabinoid receptor 1 (CB1) antagonist with a K_i value of 894 nM. (R)-SLV 319 is a dextrorotatory counterpart of SLV 319

HY-W011040

LY320135	Antagonist
LY320135 is a potent and selective antagonist of CB1 receptor, with a K_i of 141 nM. LY320135 also binds to 5-HT₂ and muscarinic receptors with K_is of 6.4 μM and 2.1 μM, respectively. LY320135 exhibits neuroprotective effect.

Name
Email *

	Sorry, but the email address you supplied was invalid.